Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Case Report

Aorta to RV Fistula: A Rare Complication of TAVR

October 2018

Abstract 

An 80-year-old man with symptomatic severe aortic stenosis presented with worsening exertional dyspnea and heart failure symptoms. He was evaluated for transcatheter aortic valve replacement (TAVR) after being deemed a high-risk surgical candidate. During the pre-procedural angiogram, significant coronary artery disease was noted, requiring stent placement to the right coronary artery prior to valve intervention. The patient subsequently underwent TAVR and required several balloon dilations intra-procedurally due to paravalvular leak. Intra-procedural transesophageal echocardiogram revealed small aortic to right ventricular fistula. A second valve was deployed without further incident. The patient also developed complete heart block during the procedure and required permanent pacemaker implantation the following day. He was managed conservatively with imaging and clinical evaluations while remaining asymptomatic from the fistula.

Introduction

Transcatheter aortic valve replacement (TAVR) is a percutaneous option for high-risk surgical patients requiring valve replacement due to severe aortic stenosis.1 Recent data presented at the American College of Cardiology 2018 Scientific Session indicates that TAVR may be a safe option for low-risk surgical patients as well.1 Major reported complications of TAVR include paravalvular leak, aortic root rupture, moderate to severe aortic insufficiency, complete heart block, ventricular arrhythmias, and stroke.2 Aorta to right ventricular (RV) fistula formation is a rare complication of surgical aortic valve surgery (SAVR) and TAVR. As of 2017, there were more than 120,000 TAVR procedures performed and only five cases of aorto-RV fistula reported.2-6

Case Report

Verma TAVR Figure 1
Figure 1. Parasternal long axis view demonstrating flow from aorta to right ventricle after CoreValve Evolut valve placement.

An 80-year-old man with a medical history of coronary artery disease requiring bypass graft surgery in 2005, colon cancer status post resection, heart failure with preserved ejection fraction, and known severe aortic valve stenosis presented with decreased exercise tolerance, fatigue, and shortness of breath. He presented with New York Heart Association (NYHA) class III symptoms which progressed over six months. Transthoracic echocardiogram (TTE) showed left ventricular ejection fraction of 55%, and severe aortic stenosis with an aortic valve area (AVA) of 0.7cm2, mean pressure gradient of 45 mmHg, and velocity of 316 cm/second. The patient’s case and images were reviewed by two cardiothoracic surgeons and the TAVR team. He was planned for TAVR as a high-risk surgical candidate, given his age and comorbidities. A pre-procedural angiogram demonstrated patent grafts from the left internal mammary artery (LIMA) to the left anterior descending artery (LAD), saphenous vein graft (SVG) to the obtuse marginal (OM) artery, and SVG to the right posterior descending artery (RPDA). A 95% stenosis in the proximal right coronary artery (RCA) with TIMI-2 flow was noted, and a bare-metal stent was successfully placed, resulting in TIMI-3 flow.

Verma TAVR Figure 2
Figure 2. Aortic short axis view demonstrating flow from aorta to right ventricular fistula. (Video available online at cathlabdigest.com.)

The TAVR procedure was performed one month later via right femoral access using the standard technique. Pre-dilatation with a 22 mm balloon was required, due to severe calcification of the valve leaflets. A 29 mm CoreValve Evolut (Medtronic) was advanced and appropriately positioned. A severe paravalvular leak was noted after valve deployment. Three serial dilatations were performed with 24 mm, 25 mm, and 28 mm balloons, respectively. Intraprocedural imaging revealed a mild paravalvular leak with a new severe central valvular leak, likely secondary to serial balloon dilatations. A second 29 mm CoreValve Evolut was subsequently deployed 3-4 mm above the initial valve with an excellent result. A transesophageal echocardiogram (TEE) revealed a small fistula between the aortic root and the right ventricle without a significant shunt. On the table, the patient developed complete heart block with a junctional escape rhythm. A temporary pacemaker was inserted, and he was monitored on telemetry throughout recovery. The following day, a permanent pacemaker was placed, secondary to persistent third-degree heart block. Post-operative TTE showed a normally functioning bioprosthetic valve, trace aortic regurgitation, calculated AVA 2.5 cm2, and a mean gradient of 6 mmHg. A fistula between the aortic root and RV was confirmed and unchanged. Mildly increased velocity across the pulmonic valve was noted without a change in RV pressure.  

The patient remained asymptomatic post-procedure and was discharged on hospital day five. He had an otherwise uneventful hospital course. At 30-day follow-up, the patient denied dyspnea, orthopnea, or lower extremity swelling. He reported an increase in exercise tolerance and his physical exam did not yield any evidence of heart failure. Repeat TTE illustrated a stable aortic to RV fistula without hemodynamic changes. The patient continues to be managed conservatively with repeat imaging and clinical evaluation three years post procedure.  

Discussion

TAVR complications include myocardial infarction, annular rupture, vascular complications, conduction disorders, paravalvular leaks, and stroke. Our case illustrates a rare complication of an aorto-RV fistula that did not require repair. The exact mechanism for the development of these fistulas post-TAVR is not fully understood. Aorto-RV fistula formation has been documented after SAVR and TAVR.2 Possible substrates for the formation of an aorto-RV fistula are the presence of congenital or acquired sinus of Valsalva aneurysms, trauma, and infections.7,8 An area between the aorta and RV, above the right coronary cusp, is a proposed site of fistula formation.4 Heavy calcification of the aortic valve and annulus, and the need for aggressive surgical debridement pre-implantation can cause local trauma or tissue displacement, leading to fistula formation.7 In the first reported case of aorto-RV fistula formation post TAVR, Pilgrim et al stated that erosion of the stent struts of the bioprosthetic valve into the aortic root might have led to the resultant fistula. 

The depth of prosthesis and larger size devices are implicated as a potential impetus for fistula development.6 In our case, debridement of the aortic valve leaflet via balloon dilation was performed pre-implantation, secondary to severe calcification. Serial post-implantation balloon dilations were required for a paravalvular leak. Either dilation mechanism had the potential to result in the fistula. Muñoz-García et al describe a case of a fistula formation following serial dilations with a 29 mm CoreValve to correct a paravalvular leak, which correlates with our case.6 

Indication for aorto to RV fistula repair is contingent on the presence and severity of symptoms. Exertional dyspnea, pedal edema, and ascites are reflective of right ventricular volume, and pressure overload may improve with fistula repair. Shunt size has been associated with symptom severity.2 A case series performed by Samuels et al describes 40 patients with post SAVR aorto-RV fistulas.8 Nearly all of the patients in this series required surgical correction of the fistula due to the development of symptoms of heart failure, with a mean interval of 1.5 years from fistula formation to repair. As an important note, 35% of the patients also had aortic valve regurgitation; therefore, it is unclear whether the postoperative symptoms were a result of the shunt or aortic regurgitation. In a review of case reports of aorto-RV fistula post TAVR, two patients with symptomatic shunts did not undergo a surgical or percutaneous correction, and died from the progression of heart failure.2,4 One case was further complicated by accompanying complete heart block and ventricular septal defect.

To date, there is no reported spontaneous closure of an aorto-RV fistula post TAVR. In asymptomatic patients, annual clinical evaluations and adjunctive echo imaging with a focus on the right ventricular and pulmonary artery pressures are crucial. In younger, symptomatic patients, correction of the fistula is prudent, given the risk of progression to heart failure.2 Surgical repair remains the first-line treatment option. Percutaneous closure procedures utilizing TEE guidance have been reported for high surgical risk patients. Pilgrim et al described a case of successful shunt elimination of an aorto-RV fistula with an IMWC-5-PDA5 coil closure (MReye Flipper Detachable Embolization Coil Delivery System, Cook Medical).5 A case series of 20 patients with ruptured sinus of Valsalva aneurysms demonstrated successful fistula closure using an Amplatzer Duct Occluder (Abbott).9 Variability in size, shape, and complexity of these defects must be kept in mind when using percutaneous devices not originally designed for aorto-RV fistula repair.7 Currently, there are no guidelines for percutaneous closure of aorto-RV fistulas. Our patient remained asymptomatic. At 30-day follow-up, TTE showed no significant change in fistula size or right ventricular dimensions, allowing for the continuation of conservative management. His symptoms and echocardiographic images remain stable and unchanged three years after TAVR.

References

  1. Thyregod HG, Steinbrüchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015 May 26; 65(20): 2184-2194.
  2. Konda MK, Kalavakunta JK, Pratt JW, et al. Aorto-right ventricular fistula following percutaneous transcatheter aortic valve replacement: case report and literature review. Heart Views. 2017 Oct-Dec; 18(4): 133-136.
  3. Kilic T, Yilmaz I. Transcatheter aortic valve implantation: a revolution in the therapy of elderly and high-risk patients with severe aortic stenosis. J Geriatr Cardiol. 2017 Mar; 14(3): 204-217.
  4. Shakoor MT, Islam AM, Ayub S. Acquired aorto-right ventricular fistula following transcatheter aortic valve replacement. Case Rep Cardiol. 2015; 2015: 608539.
  5. Pilgrim T, Meier B, Wenaweser P. Aorto-right ventricular fistula after transfemoral aortic valve implantation. J Invasive Cardiol. 2010; 22(2): E30-E31.
  6. Muñoz-García AJ, Rodríguez-Bailón I, Briales JH, et al. Aorto-right ventricular fistula after percutaneous aortic valve implantation of a CoreValve prosthesis. Tex Heart Inst J. 2011; 38(6): 728-729.
  7. Lebreiro AM, Silva JC. Transcatheter closure of an iatrogenic aorto-right ventricular fistula. Catheter Cardiovasc Interv. 2012 Feb 15;79(3): 448-452.
  8. Samuels LE, Kaufman MS, Rodriguez-Vega J, et al. Diagnosis and management of traumatic aorto-right ventricular fistulas. Ann Thorac Surg. 1998 Jan; 65(1): 288-292.
  9. Kerkar PG, Lanjewar CP, Mishra N, et al. Transcatheter closure of ruptured sinus of Valsalva aneurysm using the Amplatzer duct occluder: immediate results and mid-term follow-up. Eur Heart J. 2010; 31(23): 2881-2887.

Disclosures: Dr. Robert Frankel reports he became certified as an implanting physician proctor for Medtronic TAVR valves after this procedure, but was not at the time of the procedure. Drs Verma, Kakar, Moskovits, and Shani report no conflicts of interest regarding the content herein.

The authors can be contacted via Dr. Shivani Verma at sverma@maimonidesmed.org.


Advertisement

Advertisement

Advertisement